DR. JON D. LEVINE, M.D.
Osteopathic Medicine at Parnassus Ave, San Francisco, CA

6525062, Feb 25, 2003

Jun 8, 2001

09/877669

Jon D. Levine - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 3144

514282

Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0. 2 to about 0. 8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself). Treatment of both inflammatory and neuropathic pain can be achieved; side effects common with -opioids such as morphine were not observed.

6376467, Apr 23, 2002

Jul 6, 1999

09/347370

Robert O. Messing - Foster City CA
Jon D. Levine - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 3808

514 15, 424 92, 514 16, 5142382, 514247, 514455, 514459, 514475, 514510, 514544

The role of the isozyme of protein kinase C (“PKC ”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC , methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC and PKC -independent analgesic agent are disclosed.

6686334, Feb 3, 2004

Jan 4, 2002

10/039278

Robert O. Messing - Foster City CA
Jon D. Levine - San Francisco CA

Regents of the University of California - Oakland CA

A61K 3800

514 15, 424 92, 514 16

The role of the isozyme of protein kinase C (“PKC ”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC , methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC and PKC -independent analgesic agent are disclosed.

2004018, Sep 16, 2004

Dec 12, 2003

10/734308

Jon Levine - San Francisco CA, US

The Regents of the University of California - Oakland CA

A61K031/485

514/282000

Methods and compositions for treating, managing or ameliorating pain in a subject (preferably, a mammal, and more preferably, a human) comprising administration of a centrally acting (i.e., crosses the blood brain barrier) agonist of a -opioid receptor and a centrally acting opioid antagonist such that the analgesia achieved by this administration is greater than with administration of either the -opioid receptor agonist or the opioid antagonist alone. Preferably the -opioid receptor is nalbuphine or a salt or prodrug of nalbuphine and the opioid antagonist is naloxone or a salt or prodrug of naloxone. Preferred methods of administration include mucosal (e.g. intranasal or pulmonary) and intravenous. Other -opioid receptors include pentazocine and butorphanol.

2003000, Jan 9, 2003

Jun 14, 2002

10/173332

Jon Levine - San Francisco CA, US
Robert Messing - Foster City CA, US

The Regents of the University of California

A61K031/00, G01N033/567

514/001000, 435/007210

This invention pertains to the discovery of a novel pathway that mediates hyperalgesia, neuropathic pain, and inflammatory pain. This pathway is a third independent pathway that involves activation of extracellular signal-regulated kinases (ERKs) 1 and 2. The pathway comprises a Ras-MEK-ERK1/2 cascade that acts independent of PKA or PKC as a novel signaling pathway for the production of inflammatory (and neuropathic) pain. This pathway presents numerous targets for a new class of analgesic agents.

2004006, Apr 8, 2004

Oct 1, 2003

10/677426

Robert Messing - Foster City CA, US
Jon Levine - San Francisco CA, US

Regents of the University of California

A61K038/17

514/012000

The role of the E isozyme of protein kinase C (“PKC ”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC , methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC and PKC -independent analgesic agent are disclosed.